methyl-CpG binding protein 2
The MECP2 gene provides instructions for making a protein called MeCP2. This protein helps regulate gene activity (expression) by modifying chromatin, the complex of DNA and protein that packages DNA into chromosomes. The MeCP2 protein is present in cells throughout the body, although it is particularly abundant in brain cells.
In the brain, the MeCP2 protein is important for the function of several types of cells, including nerve cells (neurons). The protein likely plays a role in maintaining connections (synapses) between neurons, where cell-to-cell communication occurs. Many of the genes that are known to be regulated by the MeCP2 protein play a role in normal brain function, particularly the maintenance of synapses.
Researchers believe that the MeCP2 protein may also be involved in processing molecules called messenger RNA (mRNA), which serve as genetic blueprints for making proteins. By cutting and rearranging mRNA molecules in different ways, the MeCP2 protein controls the production of different versions of certain proteins. This process is known as alternative splicing. In the brain, the alternative splicing of proteins is critical for normal communication between neurons and may also be necessary for the function of other types of brain cells.
2. Health Conditions Related to Genetic Changes
2.1. MECP2 duplication syndrome
An extra copy (duplication) of the MECP2 gene in each cell causes MECP2 duplication syndrome, a condition characterized by intellectual disability, delayed development, and seizures. This condition affects males more often than females. When females are affected, they tend to have milder features. The duplication occurs on the long (q) arm of the X chromosome and includes the MECP2 gene; other genes may also be involved, depending on the size of the duplicated segment. The size of the duplication varies from 100,000 to a few million DNA building blocks (base pairs).
Duplication of the MECP2 gene leads to the production of extra MeCP2 protein and an increase in protein function. The resulting changes in gene regulation and protein production in the brain lead to abnormal neuronal function. These neuronal changes disrupt normal brain activity, causing the signs and symptoms of MECP2 duplication syndrome.
2.2. MECP2-related severe neonatal encephalopathy
At least 19 mutations in the MECP2 gene cause MECP2-related severe neonatal encephalopathy. This condition almost exclusively affects males and is characterized by small head size (microcephaly), movement disorders, breathing problems, and seizures. Many of the MECP2 gene mutations that cause this condition in males cause a similar disorder called Rett syndrome (described below) in females. Most of these mutations change single base pairs, insert or delete base pairs in the gene, or change how protein is produced from the gene. These changes in DNA alter the structure of the MeCP2 protein or reduce the amount of protein that is produced. As a result, cells do not have enough MeCP2 protein to bind to DNA and regulate other genes. A shortage of MeCP2 alters the activity of genes that are normally controlled by this protein. Mutations in the MECP2 gene may also disrupt alternative splicing of proteins critical for communication between neurons. Although these defects disrupt normal brain development, it remains unclear how MECP2 gene mutations lead to the signs and symptoms of MECP2-related severe neonatal encephalopathy.
2.3. PPM-X syndrome
Mutations in the MECP2 gene have been found to cause PPM-X syndrome. This disorder is characterized by mild to severe intellectual disability, bipolar disorder, and a pattern of movement abnormalities known as parkinsonism. This condition affects males more often than females; when females are affected, they tend to have only mild intellectual disability.
Eight particular mutations are responsible for approximately half of all cases of PPM-X syndrome. These mutations either change single protein building blocks (amino acids) in the MeCP2 protein or create a premature stop signal in the instructions for making the protein. Mutations that cause PPM-X syndrome lead to the production of a MeCP2 protein that cannot properly interact with DNA or other proteins and so cannot control the expression of genes. It is unclear how MECP2 gene mutations lead to the signs and symptoms of PPM-X syndrome, but misregulation of genes in the brain likely play a role in the development of intellectual disability and movement and mood disorders in affected individuals.
2.4. Rett syndrome
More than 620 mutations in the MECP2 gene have been identified in females with Rett syndrome, a brain disorder that causes problems with communication, learning, and coordination. These mutations include changes in single base pairs, insertions or deletions of DNA in the gene, and changes that affect how the information carried by the gene is used to produce proteins. MECP2 gene mutations alter the structure of the MeCP2 protein or reduce the amount of protein that is produced. The resulting shortage of functional MeCP2 likely impairs the regulation of gene expression in brain cells and may also disrupt alternative splicing of proteins critical for communication between neurons. Studies suggest that these changes may reduce the activity of certain neurons and impact their ability to communicate with one another. It is unclear how these changes lead to the specific features of Rett syndrome.
2.5. Other disorders
Mutations in the MECP2 gene have also been identified in people with several other disorders that affect the brain. For example, MECP2 gene mutations are associated with some cases of moderate to severe X-linked intellectual disability without other features of the syndromes described above. In addition, several people with both the features of Rett syndrome and signs and symptoms similar to Angelman syndrome (a condition characterized by intellectual disability, problems with movement, and inappropriate laughter and excitability) have mutations in the MECP2 gene. MECP2 gene mutations or changes in the gene's activity have been reported in some cases of autism spectrum disorder, which affects communication and social interaction.
3. Other Names for This Gene
- MeCP2 protein
- methyl CpG binding protein 2
- methyl CpG binding protein 2 (Rett syndrome)
The entry is from https://medlineplus.gov/genetics/gene/mecp2
- Adkins NL, Georgel PT. MeCP2: structure and function. Biochem Cell Biol. 2011 Feb;89(1):1-11. doi: 10.1139/O10-112. Review.
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rettsyndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-bindingprotein 2. Nat Genet. 1999 Oct;23(2):185-8.
- Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML,Vance JM, Pericak-Vance MA. Identification of MeCP2 mutations in a series offemales with autistic disorder. Pediatr Neurol. 2003 Mar;28(3):205-11.
- Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic toneurobiology. Neuron. 2007 Nov 8;56(3):422-37. Review.
- Gonzales ML, LaSalle JM. The role of MeCP2 in brain development andneurodevelopmental disorders. Curr Psychiatry Rep. 2010 Apr;12(2):127-34. doi:10.1007/s11920-010-0097-7. Review.
- Lombardi LM, Baker SA, Zoghbi HY. MECP2 disorders: from the clinic to mice andback. J Clin Invest. 2015 Aug 3;125(8):2914-23. doi: 10.1172/JCI78167.
- Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A,Raynaud M, Rating D, Journel H, Chelly J, Goizet C, Lacombe D, Pedespan JM,Echenne B, Tariverdian G, O'Rourke D, King MD, Green A, van Kogelenberg M, VanEsch H, Gecz J, Hamel BC, van Bokhoven H, de Brouwer AP. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% ofmale patients with severe encephalopathy. Eur J Hum Genet. 2009 Apr;17(4):444-53.doi: 10.1038/ejhg.2008.208.May;17(5):697.
- Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015 May;16(5):261-75. doi: 10.1038/nrg3897.
- McGraw CM, Samaco RC, Zoghbi HY. Adult neural function requires MeCP2.Science. 2011 Jul 8;333(6039):186. doi: 10.1126/science.1206593.
- Neul JL, Zoghbi HY. Rett syndrome: a prototypical neurodevelopmental disorder.Neuroscientist. 2004 Apr;10(2):118-28. Review.
- Samaco RC, Neul JL. Complexities of Rett syndrome and MeCP2. J Neurosci. 2011 Jun 1;31(22):7951-9. doi: 10.1523/JNEUROSCI.0169-11.2011. Review.
- Signorini C, De Felice C, Leoncini S, Møller RS, Zollo G, Buoni S, Cortelazzo A, Guerranti R, Durand T, Ciccoli L, D'Esposito M, Ravn K, Hayek J. MECP2Duplication Syndrome: Evidence of Enhanced Oxidative Stress. A Comparison withRett Syndrome. PLoS One. 2016 Mar 1;11(3):e0150101. doi:10.1371/journal.pone.0150101.
- Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, Andrews R,Bird AP. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell. 2010 Feb 26;37(4):457-68. doi:10.1016/j.molcel.2010.01.030.
- Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K,Lugtenberg D, Bienvenu T, Jensen LR, Gecz J, Moraine C, Marynen P, Fryns JP,Froyen G. Duplication of the MECP2 region is a frequent cause of severe mentalretardation and progressive neurological symptoms in males. Am J Hum Genet. 2005 Sep;77(3):442-53.
- Viana MC, Menezes AN, Moreira MA, Pissinatti A, Seuánez HN. MECP2, a geneassociated with Rett syndrome in humans, shows conserved coding regions,independent Alu insertions, and a novel transcript across primate evolution. BMC Genet. 2015 Jul 7;16:77. doi: 10.1186/s12863-015-0240-x.
- Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, Rose MF, Kang D,Richman R, Johnson JM, Berget S, Zoghbi HY. Regulation of RNA splicing by themethylation-dependent transcriptional repressor methyl-CpG binding protein 2.Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17551-8.in: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1656.
- Please check and comment entries here.